Luke Ascolillo

Luke Ascolillo is an experienced professional in clinical operations and project management with a career spanning over two decades. Currently serving as Executive Director at NextPoint Therapeutics, Inc., since September 2025, Luke has held various senior roles in clinical operations at companies including Dragonfly Therapeutics, Inc. and Alpha-9 Oncology. Previous positions include Director of Clinical Operations at Hemab Therapeutics, Director of Clinical Operations and Translational Biomarkers at Codiak BioSciences, and Senior Project Manager at Genocea Biosciences. Luke's earlier career includes roles at Tufts University in research program management and lab supervision, as well as a position as Senior Analyst at The Cadmus Group. Luke holds a Master of Science in Engineering from Tufts University and a Master of Public Health in Environmental Health from Tufts University School of Medicine, in addition to a Bachelor of Science in Biochemistry/Biophysics from Rensselaer Polytechnic Institute.